Land: Irland
Sprog: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
SEVOFLURANE
Abbott Laboratories Ireland Ltd
100 %v/v
Inhalation Vapour Liquid
1995-04-19
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0038/060/001 Case No: 2070285 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to ABBOTT LABORATORIES IRELAND LTD 4051 KINGSWOOD DRIVE, CITYWEST BUSINESS CAMPUS, DUBLIN 24, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product SEVORANE INHALATION GAS The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 12/10/2009 until 18/04/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 17/11/2009_ _CRN 2070285_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sevorane Inhalation Gas 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sevoflurane. For excipients, see 6.1 3 PHARMACEUTICAL FORM Inhalation gas Nonflammable, volatile liquid for administration as an inhalation anesthetic. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Sevoflurane is indicated for induction and maintenance of general anaesthesia in adult and paediatric patients. Use of Sevoflurane in dental anaesthesia should be restricted to hospitals or day care units only (see section 4.3). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Sevoflurane should be delivered via a vaporiser specifically Læs hele dokumentet